Advancing structural elucidation of conjugation drug metabolites in metabolite profiling with novel electron‐activated dissociation
Rapid Communications in Mass Spectrometry · 2024
DOI: 10.1002/rcm.9890 ↗Kurz gefasst
Fachartikel in der Zeitschrift Rapid Communications in Mass Spectrometry, 2024. Verfasst von Ming Yao und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Candidate Optimization, Bristol Myers Squibb, Princeton, NJ, USA. Hauptthemen laut MEDLINE: Microsomes, Liver, Tandem Mass Spectrometry, Glutathione. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Bristol Myers Squibb, Bristol-Myers Squibb Canada.
Abstract (Originalsprache)
Rationale
This study focuses on the advantage of using the novel electron‐activated dissociation (EAD) technology on the QTOF system for structural elucidation of conjugation metabolites. In drug metabolite identification, conceptual “boxes” are generally used to represent potential sites of modifications, which are proposed based on MS/MS data. Electron‐activated dissociation (EAD) provides unique fragmentation patterns, potentially allowing for more precise localization of the metabolic modification sites compared to CID, particularly for conjugations.
Method
Known compounds were incubated with rat liver microsomes in the presence of nicotinamide adenine dinucleotide phosphate (NADPH), uridine dihosphate‐glucuronic acid (UDPGA), and glutathione. Conjugation metabolites were analyzed using the QTOF system. High‐resolution MS/MS spectra were collected using EAD and CID fragmentations along with TOF MS full scan for tested drugs and metabolites. Fragmentation patterns were compared to evaluate their efficiency in structural elucidation.
Results
Metabolite profiling identified conjugation metabolites (glucuronides and GSH adducts), using characteristic mass shifts. A comparison of EAD and CID fragmentation revealed EAD‐specific fragments for most conjugates. EAD was able to break the relatively stable bonds on parent drug motifs while keeping relatively weak conjugation bonds intact, despite the generally low intensity of EAD. EAD effectively narrowed the conceptual “box” representing modification sites, providing more definitive information on conjugation sites and facilitating the structural elucidation of conjugated metabolites.
Conclusion
EAD is a powerful tool for metabolite profiling in drug development, particularly for identifying conjugation sites. EAD‐enabled MS/MS spectra offer a greater variety of signature fragments compared to CID, resulting in more comprehensive and unique structural information for metabolic modification analysis. Overall, EAD, complementary to CID, has the potential to narrow down potential modification sites, significantly enhancing the precision of conjugation metabolite structure elucidation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Candidate Optimization, Bristol Myers Squibb, Princeton, NJ, USA.
- AB Sciex, Redwood City, CA, USA.
ORCID-Profile: Nian Tong
Förderung
- Bristol Myers Squibb
- Bristol-Myers Squibb Canada
Zitieren
APA
Yao, M., Tong, N., Rahul, B., & Ruan, Q. (2024). Advancing structural elucidation of conjugation drug metabolites in metabolite profiling with novel electron‐activated dissociation. Rapid Communications in Mass Spectrometry. https://doi.org/10.1002/rcm.9890
Vancouver
Yao M, Tong N, Rahul B, Ruan Q. Advancing structural elucidation of conjugation drug metabolites in metabolite profiling with novel electron‐activated dissociation. Rapid Communications in Mass Spectrometry. 2024. doi:10.1002/rcm.9890
BibTeX
@article{Yao2024,
author = {Yao, Ming and Tong, Nian and Rahul, Baghla and Ruan, Qian},
title = {Advancing structural elucidation of conjugation drug metabolites in metabolite profiling with novel electron‐activated dissociation},
journal = {Rapid Communications in Mass Spectrometry},
year = {2024},
doi = {10.1002/rcm.9890}
}
EUVIMED